Form 4: Lisata Therapeutics Director Granted 30,456 RSUs

Lisata Therapeutics Director Heidi Henson was granted 30,456 restricted stock units, aligning her interests with shareholders.

Summary

• Heidi Henson, a Director of Lisata Therapeutics, Inc. (LSTA), acquired 30,456 shares of common stock.
• The transaction occurred on January 9, 2026, and was an acquisition (A) at a price of $0 per share.
• These shares represent restricted stock units (RSUs) granted under the Issuer's 2018 Equity Incentive Compensation Plan.
• The 30,456 RSUs are scheduled to vest on January 9, 2027.
• Following this transaction, Heidi Henson beneficially owns 85,725 shares, which includes the 30,456 unvested restricted stock units.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a neutral to slightly positive event, indicating alignment of interests and standard compensation practices, but does not provide significant new information on company performance or strategy.

Positives

• The grant of restricted stock units to a director aligns management and director interests with those of shareholders, incentivizing long-term performance.
• The equity incentive plan encourages retention and motivation of key personnel.

Negatives

• The grant of RSUs, while common, represents potential future dilution for existing shareholders upon vesting.
• The $0 transaction price indicates a grant, not an open market purchase, which might be seen as less bullish than a direct cash investment by the insider.

Risks

• Potential future dilution of existing shareholders' equity when the restricted stock units vest.
• The value of the RSUs is tied to the future stock price of Lisata Therapeutics, Inc., exposing the director to market risk.

Future Outlook

NA

Industry Context

Granting restricted stock units to directors is a standard practice in the biotechnology and pharmaceutical industries, as well as across many public companies, to attract, retain, and incentivize leadership by aligning their compensation with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a director is a common form of equity compensation, comparable to practices at other small-cap biotech firms.
• The vesting schedule (one year from grant) is a typical short-to-medium term incentive structure.
• The use of an existing equity incentive compensation plan (2018 plan) is standard for managing such grants.

Stakeholder Impact

• Shareholders: Potential for slight future dilution upon vesting of RSUs, but also improved alignment of director's interests with long-term shareholder value.
• Employees: May signal a stable compensation strategy for key personnel, potentially boosting morale.

Next Steps

• The 30,456 restricted stock units are scheduled to vest on January 9, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction primarily serves to align the director's interests with shareholders over the long term.

Keywords

Lisata Therapeutics, LSTA, Heidi Henson, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity grant, director compensation, stock plan